Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

Magenta Therapeutics Voluntarily Pauses The MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial To Investigate Drug Safety

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis